A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma

LESSONS LEARNED. Patients with hepatocellular carcinoma (HCC) often have limited therapeutic responses to the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor sorafenib, which is standard of care in advanced HCC. Targeting the activin receptor‐like kinase 1 (ALK1) and VEGF pathway...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou‐Alfa, Ghassan K., Miksad, Rebecca A., Tejani, Mohamedtaki A., Williamson, Stephen, Gutierrez, Martin E., Olowokure, Olugbenga O., Sharma, Manish R., El Dika, Imane, Sherman, Matthew L., Pandya, Shuchi S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369956/
https://www.ncbi.nlm.nih.gov/pubmed/30352941
http://dx.doi.org/10.1634/theoncologist.2018-0654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369956/
https://www.ncbi.nlm.nih.gov/pubmed/30352941
http://dx.doi.org/10.1634/theoncologist.2018-0654

Ejemplares similares